Project Studie MK 3475-252

Basic data

Title:
Studie MK 3475-252
Duration:
01/07/2016 to 28/02/2022
Abstract / short description:
Study MK 3475-252: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With
Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Haar, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.